Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (Q63595302)

From Wikidata
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
clinical trial
Language Label Description Also known as
English
Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
clinical trial

    Statements

    short name
    ADAPT-PO (English)
    0 references
    title
    A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (English)
    0 references
    start time
    March 2019
    0 references
    end time
    May 2020
    0 references
    number of participants
    1,200
    0 references
    minimum age
    18 year
    0 references

    Identifiers

     
                      Retrieved from "https://www.wikidata.org/w/index.php?title=Q63595302&oldid=2130928086"